✦ LIBER ✦

LONG-TERM TREATMENT WITH A NEW NON-ERGOT LONG-ACTING DOPAMINE AGONIST, CV 205-502, IN WOMEN WITH HYPERPROLACTINAEMIA

✍ Scribed by CARSTEN RASMUSSEN; TORBJÖRN BERGH; LEIF WIDE; JUDITH BROWNELL

Book ID: 114718793
Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 539 KB
Volume: 29
Category: Article
ISSN: 0300-0664
DOI: 10.1111/j.1365-2265.1988.tb01225.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A DOUBLE-BLIND STUDY COMPARING A NEW NON

A DOUBLE-BLIND STUDY COMPARING A NEW NON-ERGOT, LONG-ACTING DOPAMINE AGONIST, CV 205-502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINAEMIA

✍ ROY HOMBURG; CHRISTINE WEST; JUDITH BROWNELL; HOWARD S. JACOBS 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 477 KB

TREATMENT OF MACROPROLACTINOMAS WITH A N

TREATMENT OF MACROPROLACTINOMAS WITH A NEW NON-ERGOT, LONG-ACTING DOPAMINERGIC DRUG, CV 205–502

✍ JOHANNA W. van't VERLAAT; RONALD J. M. CROUGHS; JUDITH BROWNELL 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB

Antiparkinsonian activity of a non-ergot

Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease

✍ Dr. W. Poewe; G. Luef; B. Kleedorfer; M. Emre 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502,

Long-term treatment with the dopamine ag

Long-term treatment with the dopamine agonist CV 205–502 of patients with a clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma

✍ D. J. Kwekkeboom; S. W. J. Lamberts 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 587 KB